Total-body PET for assessing myofascial pain

用于评估肌筋膜疼痛的全身 PET

• 批准号: 10571508
• 负责人: Abhijit J Chaudhari
• 金额: $ 209.74万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-19 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10571508
• 关键词: Acupuncture Therapy; Address; Adult; Affect; American; Anatomy; Area; Back; Beds; Biological Markers; Butanols; Cell physiology; Chronic low back pain; Clinical; Collaborations; Complex; Cross-Sectional Studies; Data; Diagnosis; Disease; Dose; Emission-Computed Tomography; Evaluation; Facilities and Administrative Costs; Functional disorder; Goals; Grant; Health Care Costs; Health Policy; Hemoglobinopathies; Human body; Image; Imaging Device; Infiltration; Inflammation; Infrastructure; Institutes; Intervention; Intervention Studies; Label; Malignant Neoplasms; Measures; Metabolism; Methods; Monitor; Musculoskeletal Pain; Myofascial Pain Syndromes; Observational Study; Outcome Measure; Pain; Participant; Pathogenesis; Pathology; Patient Recruitments; Perfusion; Phase; Positioning Attribute; Positron-Emission Tomography; Process; Quantitative Evaluations; Randomized; Regional Perfusion; Resolution; Resources; Scanning; Sickle Cell Anemia; Societies; Source; Study Section; Syndrome; System; Testing; Time; Tissues; Trauma; United States National Institutes of Health; Visualization; Work; X-Ray Computed Tomography; arm; base; demographics; experience; fluorodeoxyglucose; follow-up; glucose metabolism; imaging biomarker; imaging modality; in vivo; industry partner; insight; interest; molecular imaging; novel; outcome prediction; potential biomarker; radiotracer; response; therapy outcome; tool; treatment arm

Project Summary Myofascial pain syndrome (MPS) is a prevalent and debilitating condition representing a significant burden to society. This syndrome may occur as an isolated condition, often localized in the lower back area, or be part of more complex clinical scenarios, such as hemoglobinopathy, inflammation, cancer and trauma, that affect the myofascial unit. There is a paucity of validated biomarkers for qualitative or quantitative assessment of MPS. The objective of this proposal is to establish novel measures derived from Total-body-Positron Emission Tomography/Computed Tomography (TB-PET/CT) as quantitative biomarkers to monitor response and predict outcomes for interventions that have potential to relieve myofascial pain. The TB-PET/CT measures we will assess include those reflective of myofascial tissue metabolism, perfusion, and fatty infiltration. These processes are intimately associated with myofascial tissue dysfunction and monitoring them may provide means to assess sources of pain. Therefore, this proposal is responsive to the RFA-AT-22-003 and addresses the interest area: “Quantitative evaluation of tissue metabolism, perfusion, oxygenation, and fatty infiltration”. The condition assessed in this proposal is chronic low back pain. We hypothesize that TB-PET/CT measures will (1) offer a unique insight into myofascial tissue pathology in this condition; and (2) provide biomarkers that will associate with myofascial tissue dysfunction and response to interventions. The proposed project will have two phases. The first is the R61 phase where we will conduct an observational, cross-sectional study. In this phase we will establish the association of quantitative TB-PET/CT measures with HEAL outcome measures and will determine TB-PET/CT measures that differentiate diseased versus healthy myofascial tissue. The second phase will be the R33 phase where we will carry out a randomized, controlled longitudinal interventional study. Participants will be randomly assigned to the intervention arm or the control arm. In this phase we will determine the capability of TB-PET/CT measures to track with changes in HEAL outcome measures in response to the intervention. We have defined quantitative transition criteria that will be applied to the imaging measures in the R61 phase before introducing them into the R33 phase. Therefore, through this work we hope to establish TB-PET/CT measures as potential biomarkers for providing the much-needed objectivity, sensitivity, and precision for characterizing myofascial tissue, and as surrogate measures for dysfunction, pain and for predicting and monitoring response to interventions.

项目摘要 肌筋膜疼痛综合征（MPS）是一种普遍且令人衰弱的疾病，代表了对社会的巨大燃烧。该综合征可能是一种孤立的疾病，通常位于下背部区域，也可能是影响肌筋膜内部单位的更复杂临床情况的一部分，例如血红蛋白病，感染，癌症和创伤。对于MPS的定性或定量评估，经过验证的生物标志物很少。该提案的目的是建立源自总体 - 斑点发射断层扫描/计算机断层扫描（TB-PET/CT）作为定量生物标志物，以监测有可能挽救肌止症疼痛的干预措施的结果。我们将评估的TB-PET/CT测量包括反映肌筋膜组织代谢，灌注和脂肪浸润的措施。这些过程与肌筋膜组织功能障碍密切相关，并且监测它们可能会提供评估疼痛来源的手段。因此，该建议对RFA-AT-22-003有反应，并解决了利益领域：“组织代谢，灌注，氧合和脂肪浸润的定量评估”。该提案中评估的病情是慢性下腰痛。我们假设TB-PET/CT措施将（1）在这种情况下对肌筋膜组织病理的独特见解； （2）提供将与肌筋膜组织功能障碍和对干预措施的反应相关的生物标志物。 拟议的项目将有两个阶段。第一个是R61阶段，我们将进行观察性的横断面研究。在此阶段，我们将建立定量TB-PET/CT测量与愈合结果测量的关联，并将确定区分患病与健康肌筋膜组织的TB-PET/CT测量结果。第二阶段将是R33阶段，我们将进行一项随机，受控的纵向介入研究。参与者将被随机分配到干预部门或控制臂。在此阶段，我们将确定TB-PET/CT措施通过响应干预措施的治疗结果度量的变化跟踪的能力。我们已经定义了定量过渡标准，该标准将应用于R61相中的成像度量，然后再将其引入R33相。因此，通过这项工作，我们希望建立TB-PET/CT措施作为潜在的生物标志物，以提供急需的客观，灵敏度和精确性，以表征肌筋膜组织，并作为功能障碍，疼痛以及预测干预措施反应和监测反应的替代测量。